AstraZeneca’s drug Tagrisso gets China nod for early lung cancer, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

China’s National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, AstraZeneca said., China’s National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, AstraZeneca said., , Read More